Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 25,945 shares, a decrease of 33.7% from the December 15th total of 39,109 shares. Based on an average daily volume of 34,460 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.7% of the shares of the company are short sold. Approximately 2.7% of the shares of the company are short sold. Based on an average daily volume of 34,460 shares, the days-to-cover ratio is presently 0.8 days.

Insider Transactions at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 16,295 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.50, for a total value of $187,392.50. Following the completion of the transaction, the insider owned 161,359 shares of the company’s stock, valued at approximately $1,855,628.50. This trade represents a 9.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 27,907 shares of company stock worth $287,280. Corporate insiders own 23.20% of the company’s stock.

Sensei Biotherapeutics Price Performance

NASDAQ SNSE traded down $1.17 during mid-day trading on Friday, hitting $10.44. The stock had a trading volume of 74,872 shares, compared to its average volume of 75,564. The firm’s 50 day moving average is $9.41 and its 200 day moving average is $9.14. The stock has a market capitalization of $13.15 million, a price-to-earnings ratio of -0.55 and a beta of 0.28. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its earnings results on Friday, November 14th. The company reported ($3.62) EPS for the quarter, beating analysts’ consensus estimates of ($4.11) by $0.49. As a group, equities research analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on SNSE shares. HC Wainwright lowered Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. Wall Street Zen raised shares of Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.